The Pursuit of Certainty: Integrated Evidence and the evolving drug development and reimbursement landscape
Watch leading experts from Pfizer, Merck, Amicus, and Certara discuss how Integrated Evidence can bridge…
CertaraSeptember 3, 2025
Designing a High-Value Drug Development Program: From Concept to First-in-Human (FIH)
Learn to design drug development programs for First-in-Human (FIH) success with biomarkers, PK/PD modeling, and…
CertaraAugust 29, 2025
Blueprint for Biotech Success: De-risking Early Development to Secure Long-Term Value
Discover strategies to cut risk, speed timelines, and boost investor confidence in early biotech development.
CertaraAugust 21, 2025
ToxStudio®: In silico tools to accelerate toxicology assessments
Watch to explore ToxStudio—in silico toxicology platform designed to address key preclinical safety challenges.
CertaraAugust 19, 2025
Population Pharmacokinetics for Belantamab Mafodotin Monotherapy and Combination Therapies in Patients with Relapsed/Refractory Multiple Myeloma
Explore comprehensive population pharmacokinetic analyses of belantamab mafodotin, evaluating both monotherapy and combination regimens in…
CertaraAugust 13, 2025
Sacituzumab Govitecan Population Pharmacokinetics: Updated Analyses Using HR+/HER2− Metastatic Breast Cancer Data From the Phase 3 TROPiCS‐02 Trial
Explore updated results from the Phase 3 TROPiCS-02 trial of Sacituzumab Govitecan in advanced HR+/HER2–…
CertaraAugust 13, 2025
Replacing Traditional TQT Studies with Model-Based Concentration-QTc (C-QTc) Analysis for Cardiovascular Safety in Drug Development
Learn how our experts use concentration-QTc (C-QTc) analysis to replace costly TQT studies, streamline QT…
CertaraAugust 6, 2025
Breaking New Ground: EMA Qualification of the Simcyp® Simulator Ushers in a New Era for PBPK Modeling
The Simcyp Simulator receives EMA qualification—the first and only PBPK platform formally qualified for any…
CertaraAugust 5, 2025
